MX341840B - Biomarcadores de microarn indicativos de la enfermedad de alzheimer. - Google Patents

Biomarcadores de microarn indicativos de la enfermedad de alzheimer.

Info

Publication number
MX341840B
MX341840B MX2013015392A MX2013015392A MX341840B MX 341840 B MX341840 B MX 341840B MX 2013015392 A MX2013015392 A MX 2013015392A MX 2013015392 A MX2013015392 A MX 2013015392A MX 341840 B MX341840 B MX 341840B
Authority
MX
Mexico
Prior art keywords
disease
alzheimer
subject
biomarkers indicative
microrna biomarkers
Prior art date
Application number
MX2013015392A
Other languages
English (en)
Spanish (es)
Other versions
MX2013015392A (es
Inventor
Dezso Zoltan
Kumar Pavan
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2013015392A publication Critical patent/MX2013015392A/es
Publication of MX341840B publication Critical patent/MX341840B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2013015392A 2011-06-27 2012-06-26 Biomarcadores de microarn indicativos de la enfermedad de alzheimer. MX341840B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161501720P 2011-06-27 2011-06-27
PCT/US2012/044202 WO2013003350A2 (en) 2011-06-27 2012-06-26 Microrna biomarkers indicative of alzheimer's disease

Publications (2)

Publication Number Publication Date
MX2013015392A MX2013015392A (es) 2014-07-14
MX341840B true MX341840B (es) 2016-09-05

Family

ID=46724591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015392A MX341840B (es) 2011-06-27 2012-06-26 Biomarcadores de microarn indicativos de la enfermedad de alzheimer.

Country Status (13)

Country Link
US (1) US9771617B2 (enExample)
EP (1) EP2723894B1 (enExample)
JP (2) JP6154809B2 (enExample)
KR (1) KR102082016B1 (enExample)
CN (1) CN103781919B9 (enExample)
AU (1) AU2012275556B2 (enExample)
BR (1) BR112013033488B8 (enExample)
CA (1) CA2840196C (enExample)
ES (1) ES2580379T3 (enExample)
IL (1) IL230034B (enExample)
MX (1) MX341840B (enExample)
RU (1) RU2639509C2 (enExample)
WO (1) WO2013003350A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022953A2 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
WO2015050835A1 (en) * 2013-10-01 2015-04-09 Advanced Genomic Technology, Llc Circulating biomarkers for alzheimer's disease and/or mild cognitive impairment
WO2015134551A1 (en) * 2014-03-03 2015-09-11 Banyan Biomarkers, Inc. Micro rna markers for diagnosis of a neurological condition
KR101583450B1 (ko) * 2014-12-01 2016-01-11 전주대학교 산학협력단 마이크로 rna id의 분석방법 및 이를 통해 도출한 대장암의 바이오마커
ES2894875T3 (es) 2015-03-13 2022-02-16 Univ Hiroshima Método para ayudar a la detección de la enfermedad de Alzheimer o de una discapacidad cognitiva moderada
US10358676B2 (en) * 2015-04-03 2019-07-23 Kaohsiung Chang Gung Memorial Hospital Methods and kits for detecting Kawasaki disease
KR101734645B1 (ko) * 2015-05-18 2017-05-11 (주)에이엔티랩스 초기 알츠하이머 병 또는 경도 인지 장애 진단 방법
EP4424704A3 (en) 2015-09-16 2024-12-25 Shimadzu Corporation Multiplex biomarker for use in evaluation of state of accumulation of amyloid b in brain, and analysis method for said evaluation
ES2734678T3 (es) * 2015-12-22 2019-12-11 Siemens Ag Firmas específicas en enfermedad de alzheimer por perfiles de miarn multicéntricos
US10262423B2 (en) * 2016-03-29 2019-04-16 Verily Life Sciences Llc Disease and fall risk assessment using depth mapping systems
WO2017186719A1 (en) * 2016-04-25 2017-11-02 Instytut Biologii Doswiadczalnej Im. Marcelego Nenckiego Polska Akademia Nauk Microrna biomarkers in blood for diagnosis of alzheimer's disease
KR101998457B1 (ko) * 2016-05-10 2019-07-10 조선대학교산학협력단 알츠하이머 질병의 진단을 위한 바이오마커
KR101992539B1 (ko) * 2016-10-21 2019-09-30 서울대학교산학협력단 miRNA 기반의 인지장애 질환 진단용 조성물 및 방법
WO2018228875A1 (en) * 2017-06-15 2018-12-20 Nestec S.A. Micro-rna biomarkers of blood-brain barrier dysfunction
WO2018236589A1 (en) * 2017-06-19 2018-12-27 St. John's University CIRCULATING SERIES MICRO-RNA BIOMARKERS AND METHODS OF DIAGNOSING ALZHEIMER'S DISEASE
AU2018300159A1 (en) * 2017-07-12 2020-02-06 Texas Tech University System MicroRNA-455-3p as a peripheral biomarker for Alzheimer's disease
US11078535B2 (en) * 2017-07-18 2021-08-03 The Trustees Of Indiana University Presymptomatic micro RNA targets for treatment of neurodegeneration pathology
WO2019081497A1 (en) * 2017-10-25 2019-05-02 Hummingbird Diagnostics Gmbh MIARN AS BIOMARKERS OF ALZHEIMER'S DISEASE
EP3707259A4 (en) * 2017-11-12 2021-08-11 The Regents of the University of California NON-CODING RNA FOR CANCER DETECTION
WO2019117306A1 (ja) 2017-12-14 2019-06-20 国立大学法人広島大学 アルツハイマー病の検出を補助する方法
CN108277271A (zh) * 2018-02-05 2018-07-13 范瑶飞 一种辅助检测阿兹海默疾病的miRNA
EP4697021A3 (en) * 2018-02-13 2026-05-20 Toray Industries DEMENTIA DETECTION KIT OR DEVICE AND METHOD
EP3807422B1 (en) 2018-06-15 2025-12-03 Universitat Autònoma de Barcelona Circulating mirnas as biomarkers for diagnosis of mild cognitive impairment and alzheimer´s disease
US20210292840A1 (en) * 2018-07-25 2021-09-23 Srnalytics, Inc. Small rna predictors for alzheimer's disease
JP6884810B2 (ja) * 2019-05-08 2021-06-09 キユーピー株式会社 情報提供装置、情報提供方法及びmiRNA重要度テーブル生成方法
US20240093297A1 (en) * 2020-07-24 2024-03-21 Otago Innovation Limited Biomarkers For Cognitive Conditions
WO2022165205A1 (en) * 2021-01-29 2022-08-04 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods for diagnosing neurodegenerative diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5965364A (en) 1990-10-09 1999-10-12 Benner; Steven Albert Method for selecting functional deoxyribonucleotide derivatives
US5767259A (en) 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
AU713667B2 (en) 1996-04-12 1999-12-09 Phri Properties, Inc. Detection probes, kits and assays
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
US6355421B1 (en) 1997-10-27 2002-03-12 Boston Probes, Inc. Methods, kits and compositions pertaining to PNA molecular beacons
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6383752B1 (en) 1999-03-31 2002-05-07 Hybridon, Inc. Pseudo-cyclic oligonucleobases
WO2001031580A2 (en) 1999-10-27 2001-05-03 Biowulf Technologies, Llc Methods and devices for identifying patterns in biological systems
US6528254B1 (en) 1999-10-29 2003-03-04 Stratagene Methods for detection of a target nucleic acid sequence
US6596490B2 (en) 2000-07-14 2003-07-22 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
AU2001280581A1 (en) 2000-07-18 2002-01-30 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
US6350580B1 (en) 2000-10-11 2002-02-26 Stratagene Methods for detection of a target nucleic acid using a probe comprising secondary structure
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
WO2003020739A2 (en) 2001-09-04 2003-03-13 Exiqon A/S Novel lna compositions and uses thereof
US6593091B2 (en) 2001-09-24 2003-07-15 Beckman Coulter, Inc. Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
JP2004161636A (ja) 2002-11-11 2004-06-10 Takeda Chem Ind Ltd 軽度認知障害または注意欠陥多動性障害治療剤
US7291488B2 (en) 2003-04-25 2007-11-06 Becton, Dickinson & Company Detection of herpes simplex virus types 1 and 2 by nucleic acid amplification
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
EP2272987A3 (en) 2004-07-09 2012-04-11 University of Pittsburgh of the Commonwealth System of Higher Education Identification of markers in esophageal cancer, colon cancer, head and neck cancer and melanoma
US20060078894A1 (en) 2004-10-12 2006-04-13 Winkler Matthew M Methods and compositions for analyzing nucleic acids
JP2006176503A (ja) * 2004-11-26 2006-07-06 Tohoku Univ 脳血管障害を伴うアルツハイマー病治療薬
RU2418068C2 (ru) * 2005-08-17 2011-05-10 Сирна Терапьютикс, Инк. Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
WO2007044937A2 (en) * 2005-10-13 2007-04-19 President And Fellows Of Harvard College Compositions and methods to modulate memory
MX2009001937A (es) * 2006-08-21 2009-04-30 Novartis Ag Biomarcadores para el progreso de la enfermedad de alzheimer.
WO2008153692A2 (en) * 2007-05-22 2008-12-18 The Brigham And Women's Hospital, Inc. Microrna expression profiling of cerebrospinal fluid
EP2160477B1 (en) * 2007-05-23 2013-08-07 Dharmacon, Inc. Micro-RNA scaffolds and non-naturally occurring micro-RNAs
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2009009439A2 (en) 2007-07-06 2009-01-15 The Regents Of The University Of California Snps associated with fatty acid composition of bovine meat and milk
WO2009009457A1 (en) * 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Alzheimer's disease-specific micro-rna microarray and related methods
EP2613149B1 (en) 2007-07-25 2014-09-17 University Of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
ES2660785T3 (es) 2007-08-22 2018-03-26 Trovagene, Inc. Métodos de uso de ARNmi para la detección de la muerte de células in vivo
EP2610342B1 (en) * 2007-09-14 2016-05-04 The Ohio State University Research Foundation MiRNA Expression in Human Peripheral Blood Microvesicles and uses Thereof
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009143379A2 (en) 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Use of extracellular rna to measure disease
CN101386848A (zh) * 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
CA2743211A1 (en) * 2008-11-12 2010-05-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods and systems of using exosomes for determining phenotypes
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2287336A1 (fr) 2009-07-31 2011-02-23 Exhonit Therapeutics SA Procédés et méthodes de diagnostic de la maladie d'Alzheimer
WO2011029903A1 (en) 2009-09-10 2011-03-17 Flemming Velin Method for the preparation of micro-rna and its therapeutic application
ES2597554T3 (es) 2009-11-04 2017-01-19 Diamir, Llc Métodos de utilización de micro-ARN de fluidos corporales para el diagnóstico y control del deterioro cognitivo leve
GB201011420D0 (en) 2010-07-06 2010-08-18 United Arab Emirates Universit Method for diagnosis
NZ606848A (en) 2010-09-22 2015-01-30 Janssen Pharmaceutica Nv 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (bace)
KR20140024270A (ko) 2010-12-30 2014-02-28 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
US8945829B2 (en) 2011-03-22 2015-02-03 Cornell University Distinguishing benign and malignant indeterminate thyroid lesions
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment

Also Published As

Publication number Publication date
ES2580379T3 (es) 2016-08-23
AU2012275556B2 (en) 2016-02-04
EP2723894B1 (en) 2016-05-11
WO2013003350A2 (en) 2013-01-03
KR20140044375A (ko) 2014-04-14
AU2012275556A1 (en) 2013-05-02
IL230034B (en) 2021-02-28
RU2639509C2 (ru) 2017-12-21
CA2840196C (en) 2022-09-20
MX2013015392A (es) 2014-07-14
CN103781919B9 (zh) 2017-09-15
CN103781919B (zh) 2017-07-04
US9771617B2 (en) 2017-09-26
JP2016214256A (ja) 2016-12-22
CN103781919A (zh) 2014-05-07
JP2014520529A (ja) 2014-08-25
RU2014102357A (ru) 2015-08-10
BR112013033488B1 (pt) 2022-03-03
US20140378439A1 (en) 2014-12-25
WO2013003350A3 (en) 2013-04-11
CA2840196A1 (en) 2013-01-03
JP6154809B2 (ja) 2017-06-28
KR102082016B1 (ko) 2020-02-26
EP2723894A2 (en) 2014-04-30
BR112013033488A2 (pt) 2017-03-01
BR112013033488B8 (pt) 2022-11-22

Similar Documents

Publication Publication Date Title
WO2013003350A3 (en) Microrna biomarkers indicative of alzheimer's disease
EA201390149A1 (ru) Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
SG10201906331TA (en) Methods for profiling and quantitating cell-free rna
MX360663B (es) Enfermedad tromboembolica.
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
IN2012DN01910A (enExample)
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
WO2015061634A3 (en) Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
EP2818108A4 (en) METHOD FOR DETERMINING GLUCOSE CONCENTRATION IN HUMAN BLOOD
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
WO2014124174A3 (en) Circulating bmec and related cells as biomarkers of cns diseases associated with the blood-brain-barrier disorders
WO2012167086A3 (en) Methods of diagnosing and treating amyotrophic lateral sclerosis
WO2012164525A3 (en) Aging biomarkers
MX359328B (es) Metodo para el diagnostico de enfermedad de niemann-pick.
EP2668288A2 (en) Complex mirna sets as novel biomarkers for lung diseases
WO2014187884A3 (en) Mirnas as non-invasive biomarkers for heart failure
EA201590495A1 (ru) Способ диагностики и лечения рака, направленный на молекулы, экспрессируемые в раковых стволовых клетках
WO2012089753A3 (en) Complex sets of mirnas as non-invasive biomarkers for glioblastoma
MX2016002529A (es) Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica.
GB201101400D0 (en) Detection method
FR2984197B1 (fr) Procede de transformation d'une surface progressive initiale
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
HK1200877A1 (en) Method for monitoring, diagnosis and/or prognosis of hypoxia related disorders using nfat5

Legal Events

Date Code Title Description
FG Grant or registration